WomenVCFund
Sector spotlight

Eldercare & Longevity Tech

Aging biology has become one of the next major healthcare frontiers — and women live longer, disproportionately bearing its costs.

$676M

raised by Function Health & Neko Health combined

Across just four total funding rounds.

$100M

Loyal’s 2026 Series C

One of the sector’s largest single rounds this year.

33

longevity startups raised capital in the last 12 months

Visible but not yet broad — a specialist-conviction market, not a standardized allocation.

Where the money is moving

Inside the category

Longevity diagnostics & biomarkers

Testing platforms aiming to catch age-related decline earlier.

  • Function Health ($298M Series B, $2.5B valuation)
  • Neko Health

Longevity biotech & therapeutics

Drug and therapeutic development targeting aging biology directly.

  • Loyal ($100M Series C)
  • NewLimit ($435M Series C)
  • Altos Labs ($3B raise)
  • BioAge Labs ($170M Series C)
  • Retro Biosciences ($90M)
  • Junevity ($20M seed)
  • Cleara Biotech ($45M)
  • Selphagy ($18M Series A)

Why this fits women investors specifically

Women live longer than men on average, meaning they disproportionately experience the later-life health conditions this sector is built to address — and disproportionately manage care decisions for aging parents and partners along the way. That lived proximity is exactly the kind of insight gender-lens investors say they look for.

How to get exposure

Dedicated longevity funds exist (Apollo Health Ventures, age1) and write checks from $500K into early-stage companies — a more direct thesis-driven entry point than most sectors here, though still a specialist rather than generalist allocation.

What to weigh before writing a cheque

  • The category doesn’t yet behave like a standardized portfolio allocation — investors are backing specific scientific theses, not buying broad sector exposure.
  • Biotech-heavy longevity plays carry longer development timelines and higher binary risk than software-driven care-economy plays.

Sources

Figures reflect the most recent public reporting as of 2026. Named companies are illustrative of funding activity, not investment recommendations.

← All sector spotlights